Will Wegovy work for me — and what affects the answer?

What does the trial evidence actually say about results?

The most honest starting point is the data. In STEP 1, adults with obesity but without type 2 diabetes lost an average of around 15% of their body weight over 68 weeks on semaglutide 2.4 mg, compared with roughly 2.4% on placebo. Those are averages across thousands of participants, which means some people lost considerably more and some lost less. A question our prescribers hear most weeks is whether the trial results will translate to the individual sitting in front of them, and the truthful answer is: probably yes, but not identically.

The mechanism behind Wegovy helps explain why most people do respond. Semaglutide activates GLP-1 receptors in the brain's appetite centres, slowing gastric emptying and reducing hunger signals. For the vast majority of people, that translates to eating less without feeling deprived. The drug doesn't override biology entirely, though, factors like your gut microbiome, baseline insulin sensitivity, and how aggressively you can tolerate dose titration all shape the outcome.

You can read more about how much weight Wegovy typically produces alongside a fuller breakdown of the trial figures, or explore the broader picture on our semaglutide information page.

Which factors make Wegovy more or less likely to work for a particular person?

Several things predict a stronger response. People who can reach and sustain the 2.4 mg maintenance dose tend to lose significantly more than those who plateau at a lower strength because of side effects. Adherence to a reduced-calorie diet and regular activity amplifies the medicine's effect, the STEP 1 participants all received lifestyle support alongside the injection. Starting BMI, age, sex and whether type 2 diabetes is present also shift the average: people with diabetes typically see modestly smaller reductions, partly because insulin resistance and other metabolic factors work against the medicine.

On the other hand, Wegovy is not suited to everyone. It is not licensed for use in pregnancy, while breastfeeding, or for those trying to conceive. It is not recommended for under-18s. A personal or family history of certain thyroid tumours, pancreatitis or specific gastrointestinal conditions requires a careful prescriber conversation before treatment begins. These aren't obscure edge cases, they're the reason a proper clinical assessment exists.

The NICE appraisal of semaglutide (TA875) recommends it for adults with at least one weight-related condition and a BMI of 35 or above on the NHS, or lower thresholds for some ethnic backgrounds. Private eligibility, per the licensed indication, begins at BMI 30. Whether you sit comfortably within those parameters, or in a more complex zone, is exactly what an assessment is designed to establish.

What should you do if Wegovy isn't producing the results you expected?

Some people start treatment and find the early weeks underwhelming. That's often a dose issue: the 0.25 mg starting dose exists to let your system adjust, not to produce dramatic results. Weight loss on Wegovy tends to accelerate as the dose increases toward the 2.4 mg maintenance level over roughly 16 weeks. Plateaus can also occur mid-treatment and are frequently temporary.

If you have been on the full maintenance dose for six months without reaching 5% weight loss, current clinical guidance says that continuing should be reviewed. That review exists to protect you, not to penalise you. It opens the door to an honest conversation about whether a different medicine, a different dose schedule, or additional support would serve you better. Our page on why Wegovy sometimes doesn't work as expected goes deeper into the specific reasons this can happen.

Practical details also matter more than people expect: when to expect the first signs that Wegovy is working is a common source of unnecessary anxiety. Results in the first two to four weeks are usually modest; the trajectory over months is what counts. Keeping the pen properly refrigerated, rotating your injection site, and taking it on the same day each week all support consistent drug levels.

Is Wegovy likely to be right for me specifically?

That question has a genuinely individual answer, and it's the one a prescriber is trained to give. The assessment matters because Wegovy interacts with your full health picture, your current medicines, your medical history, your weight-management goals. For women taking oral contraceptives there is no current evidence that semaglutide reduces pill effectiveness, unlike tirzepatide, though contraception and the washout period before trying to conceive should still be discussed with your prescriber.

If you're weighing up whether Wegovy suits your situation versus other licensed options, our dedicated page on Wegovy eligibility covers the criteria in more depth. For a broader look at the treatment landscape, the weight-loss treatment overview sets out what's available and why clinical suitability shapes every decision.

Cost is a reasonable question too. If you're researching how Wegovy pricing compares across providers, the Wegovy price comparison page explains what legitimate private treatment typically includes, and what some headline prices leave out.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day you submit it. There's no algorithm making the call. If treatment is clinically appropriate, your prescription is issued and your first pen is dispatched the same working day. If you'd like that assessment, speak to our prescribers, it's free, with no obligation.